Structures by: Manjunatha S. G.
Total: 11
C16H16ClN5O6S
C16H16ClN5O6S
Journal of Pharmaceutical Sciences (2012) 101, 664-680
a=7.909(4)Å b=9.467(5)Å c=12.484(7)Å
α=100.151(8)° β=95.950(8)° γ=97.644(9)°
C20H18ClN6O7S
C20H18ClN6O7S
Journal of Pharmaceutical Sciences (2012) 101, 664-680
a=7.512(2)Å b=9.462(3)Å c=17.198(5)Å
α=95.387(5)° β=102.271(5)° γ=110.101(5)°
Furosemide sodium salt trihydrate
C12H10ClN2O5SNa.3H2O
CrystEngComm (2014) 16, 22 4842
a=20.9184(10)Å b=10.4771(6)Å c=7.8468(4)Å
α=90.00° β=95.790(4)° γ=90.00°
Furosemide potassuium salt monohydrate
C12H10ClN2O5SK.H2O
CrystEngComm (2014) 16, 22 4842
a=18.8967(10)Å b=11.1734(6)Å c=7.3056(4)Å
α=90.00° β=91.346(5)° γ=90.00°
4-hydroxy-2-methyl-N-(5-methyl-2-thiazole)-2H-1,2-benzothiazine-3 -carboxamide 1,1-dioxide
C14H13N3O4S2
Acta Crystallographica Section C (1998) 54, 12 2001-2003
a=6.9960(10)Å b=8.1060(10)Å c=13.6020(10)Å
α=85.680(10)° β=88.360(10)° γ=74.880(10)°
(2<i>R</i>)-4-[(9<i>H</i>-Fluoren-9-ylmethoxy)carbonyl]-2-methylpiperazin-1-ium chloride
C20H23N2O2,Cl
Acta Crystallographica Section E (2011) 67, 12 o3386-o3387
a=8.3492(3)Å b=7.4954(2)Å c=14.9246(3)Å
α=90° β=90.6740(18)° γ=90°
C12H12N2O3
C12H12N2O3
Crystal Growth & Design (2012) 12, 10 4963
a=10.0985(16)Å b=7.0684(14)Å c=15.296(2)Å
α=90.00° β=96.282(14)° γ=90.00°
C18H18N2O5
C18H18N2O5
Crystal Growth & Design (2012) 12, 10 4963
a=7.9735(11)Å b=8.0661(11)Å c=25.497(3)Å
α=90.00° β=90.00° γ=90.00°
C18H18N2O5
C18H18N2O5
Crystal Growth & Design (2012) 12, 10 4963
a=7.581(5)Å b=8.673(6)Å c=13.437(12)Å
α=74.230(10)° β=84.306(15)° γ=74.627(11)°
C15H15N2O4
C15H15N2O4
Crystal Growth & Design (2012) 12, 10 4963
a=7.559(4)Å b=9.765(4)Å c=10.036(4)Å
α=87.82(3)° β=87.78(4)° γ=67.56(4)°
C36H38N4O13
C36H38N4O13
Crystal Growth & Design (2012) 12, 10 4963
a=33.756(5)Å b=7.1890(11)Å c=14.479(2)Å
α=90.00° β=106.874(16)° γ=90.00°